Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001668
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau DiseaseThe Natural History and Pathobiology and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau DiseaseThe Natural History and Pathobiology and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
Status:
COMPLETED
Status Verified Date:
1999-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The von Hippel Lindau VHL gene has recently been identified as the genetic defect resulting in a syndrome of multiple neoplasias Patients with VHL disease develop retinal angiomata renal cysts andor carcinomas CNS hemangioblastomas as well as pancreatic cysts and pheochromocytomas Investigators have shown the gene to be a tumor suppressor type proto-oncogene located at chromosomal locus 3p26 The gene includes three exons whose gene product targets a cellular transcription factor Elongin SIII Binding of the VHL proteins to two subunits of this elongation factor inhibits transcription and may play a crucial role in the clinical development of the von Hippel Lindau phenotype
Detailed Description:
The von Hippel Lindau VHL gene has recently been identified as the genetic defect resulting in a syndrome of multiple neoplasias Patients with VHL disease develop retinal angiomata renal cysts andor carcinomas CNS hemangioblastomas as well as pancreatic cysts and pheochromocytomas Investigators have shown the gene to be a tumor suppressor type proto-oncogene located at chromosomal locus 3p26 The gene includes three exons whose gene product targets a cellular transcription factor Elongin SIII Binding of the VHL proteins to two subunits of this elongation factor inhibits transcription and may play a crucial role in the clinical development of the von Hippel Lindau phenotype
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 97-N-0102 | None | None | None |